STATE OF OKLAHOMA

2nd Session of the 55th Legislature (2016)

COMMITTEE SUBSTITUTE
FOR ENGROSSED
SENATE BILL NO. 127 By: David of the Senate

and

Newell of the House

COMMITTEE SUBSTITUTE

[Oklahoma Health Care Authority – fee schedule – reimbursement and utilization rates – testing – preauthorization requirements - effective date]

BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

SECTION 1. NEW LAW A new section of law to be codified in the Oklahoma Statutes as Section 5030.6 of Title 63, unless there is created a duplication in numbering, reads as follows:

A. The Oklahoma Health Care Authority shall utilize the Clinical Laboratory Fee Schedule published by the Centers for Medicare and Medicaid Services and associated frequency guidelines when determining reimbursement and utilization rates for definitive drug testing; provided, the total amount reimbursed for such screenings in any fiscal year shall not exceed the amount reimbursed

by the Authority in fiscal year 2012. Referring clinicians are required to document medical necessity and risk status of every patient receiving definitive testing.

B. The Authority is authorized to establish preauthorization requirements for testing only for high risk frequency patients as defined by the guidelines of the CMS.

SECTION 2. This act shall become effective November 1, 2016.

55-2-9783 JM 04/07/16